RhumbLine Advisers
VOR icon

RhumbLine Advisers’s Vor Biopharma VOR Stock Holding History

RhumbLine Advisers’s Portfolio VOR Stock Details VOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.06M Buy
+57,528
New +$870K ﹤0.01% 2283
2024
Q3 		– Sell
-275
Closed -$5.5K – 4337
2024
Q2 		$5.5K Sell
275
-1,909
-87% -$61.7K ﹤0.01% 4072
2024
Q1 		$103K Buy
2,184
+34
+2% +$1.49K ﹤0.01% 3438
2023
Q4 		$96.7K Sell
2,150
-95
-4% -$3.92K ﹤0.01% 3459
2023
Q3 		$95.2K Buy
2,245
+114
+5% +$6.18K ﹤0.01% 3478
2023
Q2 		$132K Buy
+2,131
New +$195K ﹤0.01% 3422
2022
Q2 		– Sell
-817
Closed -$99K – 3245
2022
Q1 		$99K Sell
817
-100
-11% -$17K ﹤0.01% 2887
2021
Q4 		$213K Buy
917
+147
+19% +$42.4K ﹤0.01% 2818
2021
Q3 		$242K Buy
770
+193
+33% +$57.4K ﹤0.01% 2846
2021
Q2 		$215K Buy
577
+97
+20% +$47.9K ﹤0.01% 2907
2021
Q1 		$414K Buy
+480
New +$406K ﹤0.01% 2573

Other funds holding VOR

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

RhumbLine Advisers's VOR Position: Q2 2026 in Review

RhumbLine Advisers opened a new position in Vor Biopharma (VOR) in Q2 2026: 57,528 shares worth $1.06M. The stake represents ﹤0.01% of the portfolio and ranks #2283 among its holdings. This is a return to the name: RhumbLine Advisers previously reported a position in VOR as recently as Q2 2024.

RhumbLine Advisers first reported a position in VOR in Q1 2021 and has held it in 11 quarters since. 102 funds tracked by Wall St. Rank hold VOR as of Q2 2026.

  • RhumbLine Advisers held 57,528 shares of Vor Biopharma worth $1.06M as of Q2 2026.
  • Vor Biopharma was a new RhumbLine Advisers position in Q2 2026.
  • Vor Biopharma made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #2283 holding.
  • RhumbLine Advisers first reported a position in Vor Biopharma in Q1 2021 and has held it in 11 quarters since.
  • 102 funds tracked by Wall St. Rank held Vor Biopharma as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.